Imunon (IMNN) Competitors $0.79 -0.01 (-1.13%) Closing price 07/3/2025 03:53 PM EasternExtended Trading$0.80 +0.01 (+0.63%) As of 07/3/2025 04:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock IMNN vs. AVTX, IPA, RENB, KLRS, BLUE, ADVM, VRCA, DTIL, AADI, and ATRAShould you be buying Imunon stock or one of its competitors? The main competitors of Imunon include Avalo Therapeutics (AVTX), ImmunoPrecise Antibodies (IPA), Renovaro (RENB), Kalaris Therapeutics (KLRS), bluebird bio (BLUE), Adverum Biotechnologies (ADVM), Verrica Pharmaceuticals (VRCA), Precision BioSciences (DTIL), Aadi Bioscience (AADI), and Atara Biotherapeutics (ATRA). These companies are all part of the "pharmaceutical products" industry. Imunon vs. Its Competitors Avalo Therapeutics ImmunoPrecise Antibodies Renovaro Kalaris Therapeutics bluebird bio Adverum Biotechnologies Verrica Pharmaceuticals Precision BioSciences Aadi Bioscience Atara Biotherapeutics Avalo Therapeutics (NASDAQ:AVTX) and Imunon (NASDAQ:IMNN) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, dividends, media sentiment, profitability, earnings and risk. Is AVTX or IMNN more profitable? Avalo Therapeutics' return on equity of 111.00% beat Imunon's return on equity.Company Net Margins Return on Equity Return on Assets Avalo TherapeuticsN/A 111.00% 58.88% Imunon N/A -427.98%-175.03% Do institutionals and insiders have more ownership in AVTX or IMNN? 87.1% of Avalo Therapeutics shares are held by institutional investors. Comparatively, 4.5% of Imunon shares are held by institutional investors. 3.0% of Avalo Therapeutics shares are held by company insiders. Comparatively, 6.0% of Imunon shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. Which has more risk and volatility, AVTX or IMNN? Avalo Therapeutics has a beta of 0.77, indicating that its share price is 23% less volatile than the S&P 500. Comparatively, Imunon has a beta of 1.93, indicating that its share price is 93% more volatile than the S&P 500. Do analysts rate AVTX or IMNN? Avalo Therapeutics presently has a consensus price target of $30.00, indicating a potential upside of 498.80%. Imunon has a consensus price target of $15.50, indicating a potential upside of 1,859.54%. Given Imunon's higher probable upside, analysts clearly believe Imunon is more favorable than Avalo Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Avalo Therapeutics 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 3.00Imunon 0 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.75 Which has better valuation and earnings, AVTX or IMNN? Imunon has higher revenue and earnings than Avalo Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAvalo Therapeutics$440K123.31-$35.13MN/AN/AImunon$500K27.75-$18.62M-$1.36-0.58 Does the media refer more to AVTX or IMNN? In the previous week, Imunon had 1 more articles in the media than Avalo Therapeutics. MarketBeat recorded 3 mentions for Imunon and 2 mentions for Avalo Therapeutics. Avalo Therapeutics' average media sentiment score of 0.51 beat Imunon's score of -0.04 indicating that Avalo Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Avalo Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Imunon 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral SummaryAvalo Therapeutics and Imunon tied by winning 7 of the 14 factors compared between the two stocks. Get Imunon News Delivered to You Automatically Sign up to receive the latest news and ratings for IMNN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding IMNN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IMNN vs. The Competition Export to ExcelMetricImunonMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$13.86M$2.91B$5.53B$9.05BDividend YieldN/A2.44%5.24%4.03%P/E Ratio-0.5821.5627.5220.22Price / Sales27.75281.76421.02118.64Price / CashN/A42.7336.8958.07Price / Book2.737.518.045.67Net Income-$18.62M-$55.05M$3.18B$249.13M7 Day Performance6.89%4.61%2.90%3.28%1 Month Performance-43.50%4.72%3.70%5.55%1 Year Performance-41.84%5.92%36.15%21.12% Imunon Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IMNNImunon2.1204 of 5 stars$0.79-1.1%$15.50+1,859.5%-34.9%$13.86M$500K-0.5830News CoverageAVTXAvalo Therapeutics3.0623 of 5 stars$4.99+4.4%$30.00+501.2%-57.0%$51.76M$440K0.0040News CoverageIPAImmunoPrecise Antibodies1.7684 of 5 stars$1.06-4.5%$4.00+277.4%+33.5%$50.80M$18.16M-0.9180News CoverageRENBRenovaro1.1766 of 5 stars$0.29-1.3%N/A-82.4%$50.38MN/A-0.3820Gap UpKLRSKalaris TherapeuticsN/A$2.67+1.9%N/AN/A$49MN/A0.00110Positive NewsGap UpBLUEbluebird bio2.1495 of 5 stars$4.97flat$44.60+797.4%N/A$48.67M$103.95M-0.13520News CoverageADVMAdverum Biotechnologies4.25 of 5 stars$2.15-7.3%$23.80+1,007.0%-66.5%$48.47M$1M-0.34190VRCAVerrica Pharmaceuticals3.9411 of 5 stars$0.53+1.4%$8.00+1,409.1%-90.8%$48.34M$7.57M-0.4440DTILPrecision BioSciences4.5207 of 5 stars$4.20-2.3%$47.00+1,019.0%-52.9%$47.68M$68.70M-2.09200AADIAadi Bioscience0.6545 of 5 stars$1.93+1.6%$1.67-13.6%+42.1%$47.67M$25.07M-0.8540News CoverageATRAAtara Biotherapeutics4.1217 of 5 stars$7.72-3.0%$17.75+129.9%+3.9%$47.45M$128.94M-2.08330 Related Companies and Tools Related Companies AVTX Competitors IPA Competitors RENB Competitors KLRS Competitors BLUE Competitors ADVM Competitors VRCA Competitors DTIL Competitors AADI Competitors ATRA Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:IMNN) was last updated on 7/5/2025 by MarketBeat.com Staff From Our PartnersTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold prices are breaking records. But while everyone else is fixated on headlines… They're missing somet...Investors Alley | SponsoredThe mainstream media is wrong about AI — againThe mainstream media got it wrong … yet again. AI has recently turned the tech world on its head. And th...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Imunon, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Imunon With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free IMNN Stock Alerts